<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04827927</url>
  </required_header>
  <id_info>
    <org_study_id>INTELLiPOWER</org_study_id>
    <nct_id>NCT04827927</nct_id>
  </id_info>
  <brief_title>The Effect of Closed-Loop Versus Conventional Ventilation on Mechanical Power</brief_title>
  <acronym>INTELLiPOWER</acronym>
  <official_title>The Effect of Closed-Loop Versus Conventional Ventilation on Mechanical Power - a Multicenter Crossover Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Reinier de Graaf Groep</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dijklander Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several studies suggest fully-automated ventilation to ventilate with a lower amount of MP in&#xD;
      unselected ICU patients, patients after cardiac surgery, and patients with and without ARDS.&#xD;
      The current study will directly compare the amount of MP in invasively ventilated critically&#xD;
      ill patients by calculating MP breath-by-breath, using the various equations proposed in the&#xD;
      literature.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:&#xD;
&#xD;
      Mechanical ventilation can cause ventilator-induced lung injury (VILI). Lung protective&#xD;
      ventilation, consisting of a low tidal volume (VT), a low plateau pressure (Pplateau) and a&#xD;
      low driving pressure (Î”P) improves survival and shortens duration of ventilation in patients&#xD;
      with acute respiratory distress syndrome (ARDS). Lung protective ventilation may also benefit&#xD;
      critically ill patients with respiratory failure not caused by ARDS. 'Mechanical Power of&#xD;
      ventilation' (MP), the amount of energy per time transferred from the ventilator to the&#xD;
      respiratory system, is a summary variable that includes all the components that play a role&#xD;
      in VILI. With fully-automated closed-loop ventilation, these components are no longer set by&#xD;
      the operator, but under control of the algorithms in the ventilator.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To compare MP under INTELLiVENT-adaptive support ventilation (ASV), a fully-automated&#xD;
      closed-loop ventilation, with MP under conventional ventilation.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      INTELLiVENT-ASV compared to conventional ventilation results in a lower MP.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      National, multicenter, crossover, randomized clinical trial.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Invasively ventilated critically ill patients.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      The ventilator will be randomly switched between INTELLiVENT-ASV for 3 hours and conventional&#xD;
      ventilation for 3 hours. The amount of MP is calculated using various equations proposed in&#xD;
      the literature.&#xD;
&#xD;
      Study endpoints:&#xD;
&#xD;
      The primary endpoint is the amount of MP with each form of invasive ventilation.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness:&#xD;
&#xD;
      Differences in burden and risks of the two ventilation strategies compared in the current&#xD;
      study are not expected. Both modes of ventilation are interchangeably used as part of&#xD;
      standard care in the participating centers. No other interventions are performed. Neither the&#xD;
      collection of demographic and outcome data, nor the capturing of ventilation characteristics&#xD;
      causes harm to patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The amount of MP delivered with each form of invasive ventilation</measure>
    <time_frame>3 hours per ventilation mode</time_frame>
    <description>The amount of MP delivered with INTELLiVENT-ASV and conventional ventilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of ventilation</measure>
    <time_frame>first 28 days after start of ventilation</time_frame>
    <description>Duration of ventilation in survivors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-length and hospital of stay</measure>
    <time_frame>first 28 days after start of ventilation</time_frame>
    <description>Length of stay in the intensive care unit and in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28 day-mortality</measure>
    <time_frame>first 28 days after start of ventilation</time_frame>
    <description>Any death during ICU-, hospital-stay and within 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tidal volume</measure>
    <time_frame>3 hours per ventilation mode</time_frame>
    <description>Tidal volume in ml/kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>3 hours per ventilation mode</time_frame>
    <description>Respiratory rate per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pmax</measure>
    <time_frame>3 hours per ventilation mode</time_frame>
    <description>Maximum airway pressure in cmH2O</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Driving pressure</measure>
    <time_frame>3 hours per ventilation mode</time_frame>
    <description>Difference between end-inspiratory pressure and total Positieve End Expiratory Pressure in cmH2O</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Mechanical Ventilation</condition>
  <condition>Mechanical Power</condition>
  <arm_group>
    <arm_group_label>INTELLiVENT-ASV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of INTELLiVENT-ASV during 3 hours with 30 minutes wash-out time before.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Ventilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of conventional ventilation during 3 hours with 30 minutes wash-out time before.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Procedure: INTELLiVENT-ASV</intervention_name>
    <description>With INTELLiVENT-ASV, the patient's conditions, 'ARDS', 'Chronic Hypercapnia' or 'Traumatic Brain Injury' can be chosen, if applicable. The controllers for minute volume, PEEP and FiO2 are all activated, and the target shifts for etCO2 and SpO2 are adjusted, if necessary.</description>
    <arm_group_label>INTELLiVENT-ASV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Procedure: Conventional ventilation</intervention_name>
    <description>With conventional ventilation, the same etCO2 and SpO2 levels are targeted as with INTELLiVENT-ASV, but here the caregiver is fully responsible for choosing the settings.</description>
    <arm_group_label>Conventional Ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Admitted to one of the participating ICUs;&#xD;
&#xD;
          -  Receiving invasive ventilation through a standard endotracheal (i.e., oral) tube;&#xD;
&#xD;
          -  Expected to be ventilated &gt; 24 hours; and&#xD;
&#xD;
          -  Ventilation is applied by a ventilator that can provide INTELLiVENT-ASV and&#xD;
             conventional ventilation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 18 years;&#xD;
&#xD;
          -  No written informed consent;&#xD;
&#xD;
          -  Morbidly obese; and&#xD;
&#xD;
          -  Any contra-indication for use of INTELLiVENT-ASV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus J Schultz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Intensive Care, Amsterdam University Medical Centre - location AMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederique Paulus, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Intensive Care, Amsterdam University Medical Centre - location AMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura A Buiteman-Kruizinga, RN, BSc</last_name>
    <role>Study Director</role>
    <affiliation>Department of Intensive Care, Amsterdam University Medical Centre - location AMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura A. Buiteman-Kruizinga, RN, BSc</last_name>
    <phone>+31152604040</phone>
    <email>l.a.kruizinga@amsterdamumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura A Buiteman-Kruizinga, RN, BSc</last_name>
      <phone>+31627153843</phone>
      <email>l.kruizinga@rdgg.nl</email>
    </contact>
    <investigator>
      <last_name>Marcus J Schultz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anissa M Tsonas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michela Botta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura A Buiteman-Kruizinga, RN, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederique Paulus, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura A Buiteman-Kruizinga, RN, BSc</last_name>
      <phone>+31152604040</phone>
      <email>l.kruizinga@rdgg.nl</email>
    </contact>
    <investigator>
      <last_name>Pim LJ van der Heiden, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura A Buiteman-Kruizinga, RN, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dijklander Ziekenhuis</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie List</last_name>
      <email>S.List@westfriesgasthuis.nl</email>
    </contact>
    <investigator>
      <last_name>Patricia van Velzen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie List, RN, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Marcus J. Schultz</investigator_full_name>
    <investigator_title>Prof. Dr. Marcus J. Schultz</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 16, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT04827927/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

